Treatment Related Adverse Events and Monitoring of Patients Receiving Biologic or Small Molecule Therapy for Inflammatory Bowel Disease

Authors

  • Michael Stewart, MD, FRCPC Division of Digestive Care & Endoscopy, Department of Medicine, Dalhousie University, Halifax, NS

DOI:

https://doi.org/10.58931/cibdt.2024.2230

Abstract

The management of Inflammatory Bowel Disease (IBD) has evolved with the emergence of new treatment paradigms and the introduction of novel advanced therapies, including monoclonal antibodies (mAbs) and small molecules. These advanced therapies have improved disease control, but they necessitate careful pre-treatment assessment and ongoing monitoring to manage potential adverse effects and optimize patient outcomes. This review focuses on practical approaches to treatment-specific monitoring of currently available advanced therapies. 

Author Biography

Michael Stewart, MD, FRCPC, Division of Digestive Care & Endoscopy, Department of Medicine, Dalhousie University, Halifax, NS

Dr. Michael Stewart is an Assistant Professor of Medicine at Dalhousie University and a consultant gastroenterologist at the QEII Health Sciences Centre in Halifax, Nova Scotia. Dr. Stewart completed his undergraduate medical education at Dalhousie University, residency at the University of Calgary and Dalhousie University, and a fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Centre. His clinical and research interests include intestinal ultrasound, colon cancer, system innovation, and clinical trials. He is the co-Director of the Nova Scotia Collaborative IBD Program and Medical Director of the Nova Scotia Colon Cancer Prevention Program. 

References

Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108(8):1268-1276. doi:10.1038/ajg.2013.138 DOI: https://doi.org/10.1038/ajg.2013.138

Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal. 2010;36(5):1185-1206. doi:10.1183/09031936.00028510 DOI: https://doi.org/10.1183/09031936.00028510

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Jr., et al. Infliximab for Crohn's disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24(3):490-501. doi:10.1093/ibd/izx072 DOI: https://doi.org/10.1093/ibd/izx072

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644-653. doi:10.1016/j.cgh.2008.03.014 DOI: https://doi.org/10.1016/j.cgh.2008.03.014

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-721. doi:10.1056/NEJMoa1215739 DOI: https://doi.org/10.1056/NEJMoa1215739

Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis. Inflamm Bowel Dis. 2017;23(4):570-577. doi:10.1097/mib.0000000000001049 DOI: https://doi.org/10.1097/MIB.0000000000001049

Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(12):1227-1236. doi:10.1111/apt.13215 DOI: https://doi.org/10.1111/apt.13215

Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66(5):839-851. doi:10.1136/gutjnl-2015-311079 DOI: https://doi.org/10.1136/gutjnl-2015-311079

Loftus EV, Jr., Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-1365. doi:10.1111/apt.16060 DOI: https://doi.org/10.1111/apt.16060

Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15(10):1694-1706. doi:10.1093/ecco-jcc/jjab058 DOI: https://doi.org/10.1093/ecco-jcc/jjab058

Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20(3):578-590.e574. doi:10.1016/j.cgh.2021.02.025 DOI: https://doi.org/10.1016/j.cgh.2021.02.025

Gebeyehu GG, Fiske J, Liu E, Limdi JK, Broglio G, Selinger C, et al. Ustekinumab and vedolizumab are equally safe and effective in elderly Crohn's disease patients. Dig Dis Sci. 2023;68(5):1983-1994. doi:10.1007/s10620-022-07770-8 DOI: https://doi.org/10.1007/s10620-022-07770-8

Cheng D, Kochar BD, Cai T, Ananthakrishnan AN. Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor α antagonists in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2022;20(10):2366-2372.e2366. doi:10.1016/j.cgh.2022.01.013 DOI: https://doi.org/10.1016/j.cgh.2022.01.013

D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. doi:10.1016/s0140-6736(22)00467-6 DOI: https://doi.org/10.1016/S0140-6736(22)00467-6

Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebocontrolled withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031-2046. doi:10.1016/s0140- 6736(22)00466-4 DOI: https://doi.org/10.1016/S0140-6736(22)00466-4

D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940 DOI: https://doi.org/10.1056/NEJMoa2207940

Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, et al. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European Gastroenterol J. 2024. doi:10.1002/ueg2.12584 DOI: https://doi.org/10.1002/ueg2.12584

Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1). doi:10.1136/rmdopen-2022-002735 DOI: https://doi.org/10.1136/rmdopen-2022-002735

Din S, Selinger CP, Black CJ, Ford AC. Systematic reviewwith network meta-analysis: risk of Herpes Zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666-675. doi:10.1111/apt.17379 DOI: https://doi.org/10.1111/apt.17379

Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, et al. Long-term risk of Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2023;29(1):85-96. doi:10.1093/ibd/izac063 DOI: https://doi.org/10.1093/ibd/izac063

Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-1291. doi:10.1056/NEJMoa2033617 DOI: https://doi.org/10.1056/NEJMoa2033617

Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. J Crohns Colitis. 2024;18(2):264-274. doi:10.1093/ecco-jcc/jjad146 DOI: https://doi.org/10.1093/ecco-jcc/jjad146

Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler. 2022;28(12):1944-1962. doi:10.1177/13524585221102584 DOI: https://doi.org/10.1177/13524585221102584

Regueiro M, Siegmund B, Yarur AJ, Steinwurz F, Gecse KB, Goetsch M, et al. Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC Clinical Program. J Crohns Colitis. 2024. doi:10.1093/eccojcc/jjae060 DOI: https://doi.org/10.1093/ecco-jcc/jjae060

Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS Study. J Crohns Colitis. 2021;15(6):950-959. doi:10.1093/ecco-jcc/jjab016 DOI: https://doi.org/10.1093/ecco-jcc/jjab016

Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, et al. Canadian Association of GastroenterologyClinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. J Can Assoc Gastroenterol. 2021;4(4):e72-e91. doi:10.1093/jcag/gwab016 DOI: https://doi.org/10.1093/jcag/gwab016

Hastings R, Ding T, Butt S, Gadsby K, Zhang W, Moots RJ, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62(6):764-769. doi:10.1002/acr.20037 DOI: https://doi.org/10.1002/acr.20037

Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: nonmalignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36(4):312-323. doi:10.1111/j.1365-2036.2012.05189.x DOI: https://doi.org/10.1111/j.1365-2036.2012.05189.x

Winter RW, Friedman S, Nielsen J, Kjeldsen J, Nørgård BM, Larsen MD. Infliximab is not associated with a general long-term weight gain in patients with inflammatory bowel disease: a nationwide study. Am J Gastroenterol. 2022;117(5):777-784. doi:10.14309/ajg.0000000000001721 DOI: https://doi.org/10.14309/ajg.0000000000001721

Csontos Á A, Molnár A, Piri Z, Katona B, Dakó S, Pálfi E, et al. The effect of anti-TNFα Induction therapy on the nutritional status and dietary intake in inflammatory bowel disease. J Gastrointestin Liver Dis. 2016;25(1):49-56. doi:10.15403/jgld.2014.1121.251.tnf DOI: https://doi.org/10.15403/jgld.2014.1121.251.tnf

Davies SC, Nguyen TM, Parker CE, MacDonald JK, Jairath V, Khanna R. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2019;12(12):Cd012804. doi:10.1002/14651858.CD012804. pub2 DOI: https://doi.org/10.1002/14651858.CD012804.pub2

Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, et al. IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's Disease. J Crohns Colitis. 2020;14(1):23-32. doi:10.1093/ecco-jcc/jjz110 DOI: https://doi.org/10.1093/ecco-jcc/jjz110

Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. doi:10.1016/s0140-6736(22)00581-5 DOI: https://doi.org/10.1016/S0140-6736(22)00581-5

Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159-1171. doi:10.1016/s0140-6736(23)00061-2 DOI: https://doi.org/10.1016/S0140-6736(23)00061-2

Panhwar MS, Mansoor E, Al-Kindi SG, Sinh P, Katz J, Oliveira GH, et al. Risk of myocardial infarction in inflammatory bowel disease: a population-based National study. Inflamm Bowel Dis. 2019;25(6):1080-1087. doi:10.1093/ibd/izy354 DOI: https://doi.org/10.1093/ibd/izy354

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695. doi:10.1056/NEJMra043430 DOI: https://doi.org/10.1056/NEJMra043430

Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderateto-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-3140. doi:10.1161/01. Cir.0000077913.60364.D2 DOI: https://doi.org/10.1161/01.CIR.0000077913.60364.D2

Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138(10):807-811. doi:10.7326/0003-4819-138-10-200305200-00008 DOI: https://doi.org/10.7326/0003-4819-138-10-200305200-00008

Vuyyuru SK, Solitano V, Hogan M, MacDonald JK, Zayadi A, Parker CE, et al. Efficacy and safety of IL-12/23 and IL-23 inhibitors for Crohn's disease: systematic review and metaanalysis. Dig Dis Sci. 2023;68(9):3702-3713. doi:10.1007/s10620-023-08014-z DOI: https://doi.org/10.1007/s10620-023-08014-z

Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377(5):496-497. doi:10.1056/NEJMc1707500 DOI: https://doi.org/10.1056/NEJMc1707500

Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid changes after induction therapy in patients with inflammatory bowel disease: effect of different drug classes and inflammation. Inflamm Bowel Dis. 2023;29(4):531-538. doi:10.1093/ibd/izac100 DOI: https://doi.org/10.1093/ibd/izac100

Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Jr., Hart A, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55(4):464-478. doi:10.1111/apt.16712 DOI: https://doi.org/10.1111/apt.16712

Adorni MP, Papotti B, Borghi MO, Raschi E, Zimetti F, Bernini F, et al. Effect of the JAK/STAT inhibitor tofacitinib on macrophage cholesterol metabolism. Int J Mol Sci. 2023;24(16). doi:10.3390/ijms241612571 DOI: https://doi.org/10.3390/ijms241612571

Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28(1):32-40. doi:10.1093/ibd/izab011 DOI: https://doi.org/10.1093/ibd/izab011

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi:10.1056/NEJMoa2109927 DOI: https://doi.org/10.1056/NEJMoa2109927

Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82(7):901-910. doi:10.1136/ard-2022-223715 DOI: https://doi.org/10.1136/ard-2022-223715

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119-129.doi:10.1136/ard-2022-222259 DOI: https://doi.org/10.1136/ard-2022-222259

Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECTCOMPARE study. RMD Open. 2022;8(1). doi:10.1136/rmdopen-2021-002012 DOI: https://doi.org/10.1136/rmdopen-2021-002012

Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-663.doi:10.1016/s0140-6736(09)61963-2 DOI: https://doi.org/10.1016/S0140-6736(09)61963-2

Bernstein CN, Nugent Z, Singh H. Persistently high rate of venous thromboembolic disease in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2021;116(7):1476-1484. doi:10.14309/ajg.0000000000001237 DOI: https://doi.org/10.14309/ajg.0000000000001237

Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(12):857-873. doi:10.1038/s41575-021-00492-8 DOI: https://doi.org/10.1038/s41575-021-00492-8

Nguyen GC, Elnahas A, Jackson TD. The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease. J Crohns Colitis. 2014;8(12):1661-1667. doi:10.1016/j.crohns.2014.07.007 DOI: https://doi.org/10.1016/j.crohns.2014.07.007

Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021;61(1):121-130. doi:10.1093/rheumatology/keab294 DOI: https://doi.org/10.1093/rheumatology/keab294

Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, et al. REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD Research ConsortiumMulticenter National Cohort Study. Am J Gastroenterol. 2023;118(5):861-871. doi:10.14309/ajg.0000000000002129 DOI: https://doi.org/10.14309/ajg.0000000000002129

Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, et al. Harmful effects and potential benefits of antitumor necrosis factor (TNF)-α on the liver. Int J Mol Sci. 2018;19(8). doi:10.3390/ijms19082199 DOI: https://doi.org/10.3390/ijms19082199

Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol. 2021;33(5):623-630. doi:10.1097/meg.0000000000002076 DOI: https://doi.org/10.1097/MEG.0000000000002076

Kunchok A, Aksamit AJ, Jr., Davis JM, 3rd, Kantarci OH, Keegan BM, Pittock SJ, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937-946.doi:10.1001/jamaneurol.2020.1162 DOI: https://doi.org/10.1001/jamaneurol.2020.1162

Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 2010;62(11):3191-3195.doi:10.1002/art.27687 DOI: https://doi.org/10.1002/art.27687

Chow S, Patnana S, Gupta NK. Posterior Reversible encephalopathy syndrome in a patient with Crohn's disease on infliximab. J Clin Gastroenterol. 2016;50(8):687.doi:10.1097/mcg.0000000000000557 DOI: https://doi.org/10.1097/MCG.0000000000000557

Çimen Güneş E, Çolak S, Tekgöz E, Çınar M, Yılmaz S. Golimumab-induced posterior reversible encephalopathy syndrome (PRES): a case-based review. Clin Rheumatol. 2023;42(12):3407-3410. doi:10.1007/s10067-023-06771-w DOI: https://doi.org/10.1007/s10067-023-06771-w

Jordan A, Kinnucan J. Ustekinumab-associated posterior reversible encephalopathy syndrome in a patient with Crohn's disease. ACG Case Rep J. 2022;9(10):e00867.doi:10.14309/crj.0000000000000867 DOI: https://doi.org/10.14309/crj.0000000000000867

Mishra A, Seril DN. Posterior reversible encephalopathy syndrome following ustekinumab induction for Crohn's disease. Case Rep Gastroenterol. 2018;12(2):521-527.doi:10.1159/000492462 DOI: https://doi.org/10.1159/000492462

Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119-130. doi:10.1002/pds.2046 DOI: https://doi.org/10.1002/pds.2046

Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and antitumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58-64. doi:10.1016/j.cgh.2015.07.037 DOI: https://doi.org/10.1016/j.cgh.2015.07.037

Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. Jama.2014;311(23):2406-2413. doi:10.1001/jama.2014.5613 DOI: https://doi.org/10.1001/jama.2014.5613

Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87(5):468-475.doi:10.1136/jnnp-2015-310597 DOI: https://doi.org/10.1136/jnnp-2015-310597

Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the Global Clinical Programme. J Crohns Colitis. 2023;17(3):338-351. doi:10.1093/ecco-jcc/jjac141 DOI: https://doi.org/10.1093/ecco-jcc/jjac141

Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331-343. doi:10.1136/ard-2022-222543 DOI: https://doi.org/10.1136/ard-2022-222543

Downloads

Published

2024-09-11

How to Cite

1.
Stewart M. Treatment Related Adverse Events and Monitoring of Patients Receiving Biologic or Small Molecule Therapy for Inflammatory Bowel Disease. Can IBD Today [Internet]. 2024 Sep. 11 [cited 2024 Nov. 21];2(2):19–27. Available from: https://canadianibdtoday.com/article/view/2-2-Stewart

Issue

Volume 2, Issue 2, Summer 2024

Section

Articles

License

Copyright (c) 2024 Canadian IBD Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.